GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class:
Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. Japan PMDA (2012) | US FDA (2018) | EU EMA (2018) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9374 | mogamulizumab |
Synonyms ![]() |
| KW-0761 | mogamulizumab-kpkc | Poteligeo® |
Database Links ![]() |
|
| Specialist databases | |
| GPCRdb Ligand | mogamulizumab |
| IMGT/mAb-DB | 366 |
| Other databases | |
| GtoPdb PubChem SID | 178103091 |
| PubChem SID | 178103091 |
| Search PubMed clinical trials | mogamulizumab |
| Search PubMed titles | mogamulizumab |
| Search PubMed titles/abstracts | mogamulizumab |
| Wikipedia | Mogamulizumab |